Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.
Mikhael JR et al. Br J Haematol. 2015 Feb 13. doi: 10.1111/bjh.13296. [Epub ahead of print].

Everolimus (RAD001) Activity in Relapsed and/or Refractory Multiple Myeloma: A Phase I Study.
Guenther A et al. Haematologica. 2015 Feb 14. pii: haematol.2014.116269. [Epub ahead of print].

Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed/RefractoryMultiple Myeloma.
Berdeja JG et al. Haematologica. 2015 Feb 20. pii: haematol.2014.119735. [Epub ahead of print].

Cord blood transplantation for multiple myeloma: study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Kawamura K et al. Biol Blood Marrow Transplant. 2015 Feb 20. pii: S1083-8791(15)00122-6. doi: 10.1016/j.bbmt.2015.02.015. [Epub ahead of print].

Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.
Suzuki K et al. Int J Hematol. 2015 Feb 6. [Epub ahead of print].

GRP78-directed Immunotherapy in relapsed or refractory multiple myeloma- results from a Phase 1 Trial with monoclonal IgM antibody PAT-SM6.
Rasche L et al. Haematologica. 2015 Jan 30. pii: haematol.2014.117945. [Epub ahead of print].